Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)

被引：0

作者：

Horn, L. ^{[1
]}

Brahmer, J. ^{[2
]}

Reck, M. ^{[3
]}

Borghaei, H. ^{[4
]}

Spigel, D. R. ^{[5
]}

Steins, M. ^{[6
]}

Ready, E. ^{[7
]}

Chow, L. Q. ^{[8
]}

Vokes, E. E. ^{[9
]}

Felip, E. ^{[10
]}

Holgado, E. ^{[11
]}

Barlesi, F. ^{[12
]}

Kohlhaeufl, M. ^{[13
]}

Burgio, M. A. ^{[14
]}

Fayette, J. ^{[15
]}

Gettinger, S. N. ^{[16
]}

Harbison, C. T. ^{[17
]}

Li, A. ^{[18
]}

Finckenstein, F. G. ^{[19
]}

Paz-Ares, L. ^{[20
]}

机构：

[1] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA

[2] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA

[3] LungenClin Grosshansdorf, Grosshansdorf, Germany

[4] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA 19111 USA

[5] Sarah Cannon Res Inst, Ctr Canc, Med Oncol, Nashville, TN USA

[6] Thoraxklin Heidelberg, Internal Med Oncol, Heidelberg, Germany

[7] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA

[8] Univ Washington, Dept Med, Seattle Canc Care Alliance, Seattle, WA USA

[9] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA

[10] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain

[11] Hosp Madrid Norte, San Chinarro Ctr Integral Oncol Clara Campal, Serv Oncol, Madrid, Spain

[12] Hop Nord Marseille, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France

[13] Klin Schillerhohe, Pneumonol & Pulm Oncol, Gerlingen, Germany

[14] Ist Sci Romagnolo Studio & Cura Tumori, Dept Med Oncol, Meldola, Italy

[15] Ctr Leon Berard, Oncol Med, F-69373 Lyon, France

[16] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA

[17] Bristol Myers Squibb Co, ImmunoSci Metab Dis & Fibrosis, Princeton, NJ USA

[18] Bristol Myers Squibb Co, Oncol, Princeton, NJ USA

[19] Bristol Myers Squibb Co, Oncol Global Clin Res, Princeton, NJ USA

[20] Hosp Univ Virgen del Rocio, Serv Oncol Med, Seville, Spain

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

417O

引用

页码：125 / 125

页数：1

共 50 条

[21] Successful completion of EGFR/ALK testing in non-squamous non-small cell lung cancer (non-sq NSCLC) with the implementation of reflex testing (RT) by pathologists.
Menjak, Ines B.
Winterton-Perks, Zoe
Raphael, Simon
Cheng, Susanna Y.
Verma, Sunil
Freedman, Ryan
Toor, Nevkeet
Perera, Joseph
Anaka, Matthew
Victor, Charles
Cheema, Parneet Kaur
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)
[22] COST-UTILITY OF NIVOLUMAB AGAINST DOCETAXEL FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN UNITED ARAB EMIRATES (UAE)
Lecca, Garrido S.
Alhammad, A.
Dawood, S.
VALUE IN HEALTH, 2017, 20 (05) : A112 - A113
[23] Patient-Reported Outcomes (PROs) in Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): PERLA Trial Comparing First-Line Chemotherapy Plus Dostarlimab or Pembrolizumab
Reck, Martin
Granados, Ana Laura Ortega
de Marinis, Filippo
Meyers, Oren
Shen, Qin
Cho, Lillian
Boklage, Susan
Gouldin, Winston
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E26 - E27
[24] Advanced non-small cell Lung Cancer (NSCLC) Nivolumab in advanced NSCLC with Squamous Epithelial Histology
Sankawa, Yuri
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 149 - 149
[25] Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC)
Bordoni, R.
Ciardiello, F.
Von Pawel, J.
Cortinovis, D.
He, P.
Karagiannis, T.
Ballinger, M.
Sandler, A.
Yu, W.
Felizzi, F.
Rittmeyer, A.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1913 - S1914
[26] Phase II Trial of Carboplatin, Pemetrexed, Bevacizumab in Advanced non-Small Cell (non-Squamous) Lung Cancer
Guarino, Michael J.
Masters, Gregory A.
Biggs, David D.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S698 - S698
[27] Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC)
Tassinari, D.
Drudi, F.
Carloni, F.
Nicoletti, S.
Possenti, C.
Santelmo, C.
Lazzari, L.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[28] EGFR mutation testing trends for patients with metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) in Queensland, Australia from 2014-2021.
Yang, Zane
Niranjan, Navin
Guan, Tracey
Mason, Robert
Chan, Bryan Anthony
Sanmugarajah, Jasotha
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[29] Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC).
Nishio, Makoto
Hida, Toyoaki
Nakagawa, Kazuhiko
Sakai, Hiroshi
Nogami, Naoyuki
Atagi, Shinji
Takahashi, Toshiaki
Nokihara, Hiroshi
Saka, Hideo
Takenoyama, Mitsuhiro
Fujita, Shiro
Tanaka, Hiroshi
Takeda, Koji
Satouchi, Miyako
Isobe, Hiroshi
Maemondo, Makoto
Goto, Koichi
Hirashima, Tomonori
Minato, Koichi
Tamura, Tomohide
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[30] Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer
Rosell, Rafael
Gonzalez-Cao, Maria
LANCET, 2021, 397 (10274): : 557 - 559

← 1 2 3 4 5 →